Radium
-
Subject Areas on Research
- A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
- A critical review on the occurrence and distribution of the uranium- and thorium-decay nuclides and their effect on the quality of groundwater.
- ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223.
- Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
- Association of leukemia with radium groundwater contamination.
- Carcinoma of the tonsillar region: a multivariate analysis of 243 patients treated with radical radiotherapy.
- Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
- Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
- Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
- Geochemical evidence for possible natural migration of Marcellus Formation brine to shallow aquifers in Pennsylvania.
- High Naturally Occurring Radioactivity in Fossil Groundwater in the Middle East
- Leukemia and groundwater contamination.
- Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis etiology.
- Naturally Occurring Radioactive Materials in Uranium-Rich Coals and Associated Coal Combustion Residues from China.
- New and emerging therapies for bone metastases in genitourinary cancers.
- Occurrence and Sources of Radium in Groundwater Associated with Oil Fields in the Southern San Joaquin Valley, California.
- Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.
- Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.
- Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
- Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
- Prostate cancer, version 1.2014.
- Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.
- Racial Discrepancies in Overall Survival among Men Treated with 223Radium.
- Radical hysterectomy with preoperative intracavitary therapy for stage IB squamous cell carcinoma of the cervix.
- Radical radiotherapy for T4 carcinoma of the skin of the head and neck: a multivariate analysis.
- Radium and barium removal through blending hydraulic fracturing fluids with acid mine drainage.
- Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.
- Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
- Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
- Response to Comment on "High naturally occurring radioactivity in fossil groundwater from the Middle East".
- S-values for radium-223 and absorbed doses estimates for 223RACL2 using three computational phantoms.
- Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
- Sources of Radium Accumulation in Stream Sediments near Disposal Sites in Pennsylvania: Implications for Disposal of Conventional Oil and Gas Wastewater.
-
Keywords of People
- Vengosh, Avner, Nicholas Distinguished Professor of Environmental Quality, Nicholas Institute-Energy Initiative